北美多发性硬化症治疗市场 – 行业趋势和 2030 年预测

北美多发性硬化症治疗市场分析和规模

众多传染病给全球医疗保健系统带来的负担不断增加，是市场增长的主要原因。与去年相比，随着多发性硬化症发病率的上升，对更好的多发性硬化症治疗方案的需求不断增加，政府举措也不断增加，多发性硬化症治疗需求也随之增加。发达国家和发展中国家的政府和非政府组织正在努力提高人们对多发性硬化症的认识，并为药物研究提供大量资金。

Data Bridge Market Research 分析，多发性硬化症治疗市场预计到 2030 年将达到 57.3778 亿美元，即 2022 年为 28.796 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 9%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

北美多发性硬化症治疗市场范围和细分

Market Definition

Multiple sclerosis (MS) is a chronic and inflammatory immune-mediated condition that can cause axonal transection, demyelination, and neurodegeneration of the spinal cord and brain nerve cells. The symptoms depends on the amount of damaged nerves and the form and position of affected nerves. The multiple sclerosis causes numerous types of symptoms which includes pain, fatigue, vision loss, and impaired coordination. This disease duration, symptoms, and severity vary from person to person.  

North America Multiple Sclerosis Treatment Market Dynamics

Drivers

• Increasing Drug Development Processes by Several Market Players

Several pharmaceutical companies have also been investing heavily in the drug development process. They are planning to target different indications to attract a large number of customers. For instance, the drugs developed for multiple sclerosis include Secondary progressive MS, Primary progressive MS, Relapsing-remitting MS, and Myelin repair or neuroprotection. For instance, Novartis received European Commission approval for Kesimpta (ofatumumab) in March 2021, for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features. Thus, this factor boosts the market growth.

• Rising Demand of Branded Drugs

The rising demand of branded drugs increase the growth of the market. The demand is increasing because of the large number of products launched from time-to-time by numerous companies, making it difficult for generics to overpower it. Furthermore, the FDA approved the branded drugs when a New Drug Application is submitted with proof of stability, efficacy, dosage form, manufacture, safety, labelling, chemistry, and packaging, which largely increases its demand. Thus, it will boost the market growth.

Opportunities

• Increasing Product Launches

There have been increasing drug launches to treat multiple sclerosis, enhancing the market growth. For instance, Mylan N.V. announced the launch of its first FDA-approved generic drug dimethyl fumarate delayed-release capsules 120 mg and 240 mg used for the treatment of relapsing forms of multiple sclerosis (MS). The newly launched drug is almost similar therapeutically to the Biogen's Tecfidera capsules. This new FDA approved drug launched by the company during the COVID-19 pandemic has increased its demand in the market.

• Growing Demand of Oral Route of Administration

Several novel oral drugs recently approved for treating multiple sclerosis represent major advances in therapy. The oral route of administration offers patient satisfaction and increases therapeutic compliance. For instance, The European Commission (EC) approved Aubagio (teriflunomide) in June 2021, for the treatment of pediatric patients aged 10 to 17 years suffering from relapsing-remitting multiple sclerosis (RRMS). Aubagio is the first oral multiple sclerosis (MS) therapy applicable for first-line treatment of children and adults with MS in the European Union. Additionally, Bristol-Myers Squibb Company received U.S. FDA approval for ZEPOSIA (ozanimod) 0.92 mg in March 2020, for the treatment of adults with relapsing forms of multiple sclerosis (RMS), along with relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. Thus, this factor enhances the market growth rate.

Restraints/Challenges

• Side-Effects of Multiple Sclerosis Medications

There are various adverse effects that are associated with multiple sclerosis that impedes the growth of the market. Effects such as flu-like symptoms, chest pain, fluctuation in heart rate, rare brain infection, and chemotherapy-like effects hampers patients' adoption of multiple sclerosis drugs. This factor is anticipated to limit the market growth.

This multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2020, Genzyme Corporation signed an acquisition agreement with Principia Biopharma Inc. The main motive behind this acquisition was to improve its research activities in the field of multiple sclerosis and other immune-mediated diseases.
• In 2020, Novartis announced that the U.S. FDA approval for Kesimpta in the form of an injection for subcutaneous use for treating the relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

North America Multiple Sclerosis Treatment Market Scope

多发性硬化症治疗市场根据疾病类型、治疗、药物类型和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

疾病类型

• 复发缓解型多发性硬化症 (RRMS)
• 继发性进行性多发性硬化症 (SPMS)
• 原发性进行性多发性硬化症 (PPMS)
• 严重复发缓解型多发性硬化症 (RES)

治疗

• 预防疗法
• 急性加重的终止疗法/治疗
• 对症治疗

药物类型

• 品牌
• 通用的

给药途径

• 口服
• 肠外

终端用户

• 医院和诊所
• 诊断实验室
• 其他的

多发性硬化症治疗区域分析/见解

对多发性硬化症治疗市场进行了分析，并根据上述疾病类型、治疗、药物类型和最终用户提供了市场规模洞察和趋势。

多发性硬化症治疗市场报告涵盖的国家包括北美的美国、加拿大和墨西哥。

由于美国引入了最新的多发性硬化症治疗方案，预计美国将在 2023 年至 2030 年的预测期内引领市场。该地区药物研发的不断增加也促进了市场的增长。人们对多发性硬化症及其治疗的认识不断提高，有助于引领市场增长。  

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和北美多发性硬化症治疗市场份额分析

多发性硬化症治疗市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对多发性硬化症治疗市场的关注有关。

多发性硬化症治疗市场的一些主要参与者包括：

• AbbVie Inc.（美国）
• Bausch Health Companies Inc.（加拿大）
• Biora Therapeutics, Inc（美国）
• 勃林格殷格翰国际有限公司 (德国)
• 安进公司 (美国)
• 辉瑞公司 (美国)
• F. Hoffmann-La Roche Ltd（瑞士）
• Mylan NV（美国）
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 百时美施贵宝公司 (美国)
• Biogen（美国）
• 梯瓦制药工业有限公司 (以色列)
• 武田药品工业株式会社 (日本)
• Jazz Pharmaceuticals, Inc（英国）
• 雅培（美国）
• Bio-Rad Laboratories Inc.（美国）
• Mylan NV（美国）

SKU-56751